AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3259087
Drug: Ketamine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.5 mg/kg intravenous bolus for induction and 50 micrograms/kg/minute continuous infusion for maintenance
Trial: 22297
Drug: Pindolol administered
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol administered before bronchoscopy
Trial: 21452932
Drug: Combined endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endocrine therapy and radiotherapy
Trial: 19728936
Drug: Epidural Steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Steroid Injections (80 mg of methylprednisolone with 3 ml of 2% plain xylocaine and 3 ml of normal saline)
Trial: 19728936
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management (bed rest, non-steroidal anti-inflammatory agents, muscle relaxants, and opioids)
Trial: 8648369
Drug: Epirubicin doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin doses >60 mg/m2
Trial: 8648369
Drug: Epirubicin doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin doses
Trial: 1523876
Drug: MDP‐virosome vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDP‐virosome vaccine
Trial: 8034508
Drug: HA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA vaccine
Trial: 28010050
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of intravenous iron isomaltoside
Trial: 19803232
Drug: J in
RxNorm normalized name: IOTROLAN 240MG/ML INJ INTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J in three‐needle therapy
Trial: 10788542
Drug: CPH 82
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 1.11 g in 13.0 mL TOPICAL SPRAY [CPH Anti-bacterial Breath Mist]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPH 82 300 mg/day
Trial: 9058219
Drug: Lidoflazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine (1 mg/kg)
Trial: 4037714
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of Primperan
Trial: 31127399
Drug: Optimized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized formulation of nifedipine (3.083 mg HPMC K15M, 29.859 mg HPMC E15LV, 3.541 mg Carbopol 974P)
Trial: 31127399
Drug: Optimized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized formulation of nifedipine
Trial: 31240769
Drug: Symptom frequency
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom frequency (daily or weekly)
Trial: 25213157
Drug: Recovery-focused cognitive-behavioural
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery-focused cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Trial: 23683793
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/day + Guanfacine 1 mg/day (N/G)
Trial: 23683793
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/day + Guanfacine placebo (N/P)
Trial: 23683793
Drug: Naltrexone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone placebo + Guanfacine (P/G)
Trial: 18971892
Drug: Magnet patch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnet patch (M)
Trial: 18971892
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (P)
Trial: 11002408
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA; Tiobec) 600 mg per day for 20 days followed by 200 mg per day for 10 days
Trial: 11002408
Drug: Cellulose starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose starch 100 mg per day as placebo
Trial: 9216279
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluid (W‐i.v.f.)
Trial: 9216279
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature intravenous fluid (RT‐i.v.f.)
Trial: 8484502
Drug: Ephedrine infusion
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine infusion (5 mg/min for the first 2 min, then 1 mg/min for the next 18 min)
Trial: 8484502
Drug: Crystalloid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalloid administration (15 mL/kg)
Trial: 23901264
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + IFN‐α (3 million IU) 3 times per week (group B)
Trial: 23901264
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + IFN‐γ (3 million IU) 3 times per week (group C)
Trial: 23901264
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + IFN‐α and IFN‐γ (1.5 million IU of each) 3 times per week (group D)
Trial: 7782031
Drug: Recombinant a2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant a2 interferon (Roferon) 6 MU x 7 days every 3 weeks, Adriamycin 60 mg/m2 i.v. once every 3 weeks, Tamoxifen 10 mg p.o. twice daily continuously, Desferrioxamine 500 mg i.m. daily x 7 days every 3 weeks, Ascorbic acid 300 mg p.o. daily 1 hour after DFO x 7 days every 3 weeks
Trial: 2236463
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate maintenance doses (600 mg to 1,500 mg/day)
Trial: 346191
Drug: Fluorescent antibody
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescent antibody method for detection of estrogen receptors
Trial: 25960116
Drug: PFJ-targeted exercise,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFJ-targeted exercise, education, manual-therapy and taping program
Trial: 24057079
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (group I) with 1 intravaginal ovule containing 30 mcg estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live bacteria) once daily for 2 weeks, then two ovules once weekly for a total of 6 months plus pelvic floor rehabilitation.
Trial: 24057079
Drug: Intravaginal estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation (group II).
Trial: 23247908
Drug: Crushed IRO‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed IRO‐A (15 mg)
Trial: 23247908
Drug: Crushed IRO
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed IRO (15 mg)
Trial: 12455823
Drug: Pool exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pool exercise therapy and education
Trial: 11270999
Drug: Domestic 5-isosorbide
RxNorm normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domestic 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Trial: 11270999
Drug: Imported 5-isosorbide
RxNorm normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imported 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Trial: 11270999
Drug: Both domestic
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both domestic and imported capsules
Trial: 1478035
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg three times daily for 3 months)
Trial: 26599983
Drug: Nonselective β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonselective β-blockers (NSBBs)
Trial: 24943829
Drug: Usual health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual health classes including drug education
Trial: 17451612
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy/meditation intervention (4 one-hour sessions)
Trial: 17451612
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control (3 months before receiving treatment)
Trial: 12424105
Drug: Intravenous 2
RxNorm normalized name: Premarin Intravenous 25 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2 mg/kg of [13C]Phe
Trial: 1714885
Drug: Flecainide 150
RxNorm normalized name: flecainide 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 150 mg twice daily
Trial: 30875313
Drug: NP (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP (no cavity preparation, control)
Trial: 30875313
Drug: MOD3 (3.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD3 (3.0-mm-deep MOD preparation, not restored)
Trial: 30875313
Drug: MOD3R (3.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD3R (3.0-mm-deep MOD preparation restored with RBC)
Trial: 30875313
Drug: MOD5 (5.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD5 (5.0-mm-deep MOD preparation, not restored)
Trial: 30875313
Drug: MOD5R (5.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD5R (5.0-mm-deep MOD preparation restored with RBC)
Trial: 30875313
Drug: MOD3RC (3.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD3RC (3.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Trial: 30875313
Drug: MOD5RC (5.0-mm-deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD5RC (5.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Trial: 29191194
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine (HM) services utilization
Trial: 27614789
Drug: Intralipid (2mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (2mL diluted at 20% in 250mL saline) infusion
Trial: 27614789
Drug: Saline (250mL)
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (250mL) infusion
Trial: 22562540
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine topical spray
Trial: 22562540
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water topical spray
Trial: 20165986
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy comprising intravenous application of platinum and paclitaxel
Trial: 16273808
Drug: Finnish RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Finnish RA Combination Therapy Trial (FIN-RACo)
Trial: 12421195
Drug: Dopexamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (1 micro g. kg‐1. min‐1) continuously after induction of anesthesia until 18 h after CPB
Trial: 12421195
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine 0.25% [(body height (cm) - 100). 10-1=ml.h-1] for the whole study period
Trial: 18211117
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg and dimenhydrinate 40 mg three times daily for 4 weeks
Trial: 18211117
Drug: Betahistine 12
RxNorm normalized name: betahistine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 12 mg three times daily for 4 weeks
Trial: 16608150
Drug: Real beer
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real beer (mean breath alcohol concentration of .115 g%)
Trial: 12915338
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 to 3000 mg/day
Trial: 10789176
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with sponge anesthesia and intraocular injection of 0.15 ml lidocaine 1%
Trial: 10789176
Drug: Peribulbar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injection of 6 ml Xylonest 2%
Trial: 8795476
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine patch (Transderm, 0.05 mg/h)
Trial: 10399774
Drug: Placebo skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo skin patch
Trial: 30905926
Drug: Insulin group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin group
Trial: 26952590
Drug: 20-mg oral
RxNorm normalized name: istradefylline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg oral d-amphetamine
Trial: 23396551
Drug: Traditional anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anti-hypertensive therapy (Control)
Trial: 22125196
Drug: Capsule Endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Endoscopy Crohn's Disease Activity Index (CECDAI)
Trial: 11994349
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DNG
Trial: 11994349
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg DNG
Trial: 11994349
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DNG
Trial: 9705044
Drug: Amlodipine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (up to 10 mg)
Trial: 9705044
Drug: Lisinopril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (up to 20 mg)
Trial: 9705044
Drug: Both Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Amlodipine and Lisinopril
Trial: 2142292
Drug: fenoterol after
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol after a prior single administration of prednisone
Trial: 688256
Drug: cis‐dichlorodiammineplatinum(II) (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis‐dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m2/day by iv push on Days 1‐5 every 4 weeks, followed by cyclophosphamide (C) at a dose of 400 mg/m2 and adriamycin (A) at a dose of 40 mg/m2 upon progression or renal toxic effects.
Trial: 688256
Drug: C‐A (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐A (cyclophosphamide and adriamycin) at a dose of 400 mg/m2 and 40 mg/m2 respectively, given by iv push on Day 1 every 4 weeks.
Trial: 688256
Drug: CAP‐I (C‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP‐I (C‐A plus concurrent P at 40 mg/m2 by IV push on Day 1 every 4 weeks).
Trial: 28923098
Drug: Baricitinib +
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib + MTX (4 mg once daily + MTX administered once weekly)
Trial: 15848574
Drug: EC‐MPS 720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.)
Trial: 15848574
Drug: EC‐MPS 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 450 or 432 mg/m2 b.i.d. for children
Trial: 15848574
Drug: MMF (<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (< or =1000 mg b.i.d.)
Trial: 11888226
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 5 microg/kg followed by 0.3 microg/kg per hour infusion
Trial: 11888226
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 3 microg/kg followed by 0.3 microg/kg per hour infusion
Trial: 11888226
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 2 microg/kg followed by 0.3 microg/kg per hour infusion
Trial: 11888226
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% bolus and continuous infusion
Trial: 11888226
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (all doses)
Trial: 9498511
Drug: Splanchnic/antioxidant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splanchnic/antioxidant therapy (folate, mannitol, low-dose isoproterenol)
Trial: 9498511
Drug: Splanchnic/antioxidant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splanchnic/antioxidant therapy group
Trial: 18475395
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline
Trial: 353464
Drug: Silymarin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (2 sugar-coated tablets 70 mg three times daily)
Trial: 18986845
Drug: Sclerosant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerosant therapy
Trial: 18986845
Drug: Bolus followed
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus followed by continuous-infusion proton pump inhibitor
Trial: 15562880
Drug: Sublingual swallow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual swallow immunotherapy with ragweed allergen extract
Trial: 11566454
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone treatment (6 mg/day)
Trial: 7821475
Drug: Amethocaine cream
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amethocaine cream
Trial: 3076791
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (continuous infusion and 6‐hourly divided dose regimens)
Trial: 29071556
Drug: Probucol combined
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol combined with hydration (probucol 500 mg twice daily and hydration)
Trial: 17609022
Drug: Trichloracetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichloracetic acid or podophyllin 25% (single therapy)
Trial: 15625221
Drug: Educational video
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational video about the consent process in treatment research
Trial: 9462166
Drug: Alpha-tocopherol (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (Vitamin E) 600 mg twice a day for 12 weeks
Trial: 7949636
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of cisapride (5 mg)
Trial: 7949636
Drug: Oral cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cisapride (15 mg TID) for 14 days
Trial: 7949636
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of cisapride (5 mg) after 14 days of treatment
Trial: 31690049
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg/bm)
Trial: 25727442
Drug: Varenicline tablets
RxNorm normalized name: Varenicline Tablets
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline tablets
Trial: 23843980
Drug: Gatifloxacin regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin regimen (for drug-resistant patients)
Trial: 23843980
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (for drug-resistant patients)
Trial: 19346845
Drug: Sublingual nitroglycerine
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerine (NTG)
Trial: 16720918
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg, three times daily) and alpha-tocopherol (300 mg, twice daily) during radiotherapy, followed by 400 mg of PTX and 300 mg of alpha-tocopherol daily for 3 months after radiotherapy
Trial: 11743460
Drug: Sepragel sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepragel sinus (hylan B gel)
Trial: 28741390
Drug: Low maternal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low maternal haemoglobin level (<130 g/L) in the first trimester
Trial: 28741390
Drug: High maternal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High maternal haemoglobin level (≥130 g/L) in the second trimester
Trial: 25179587
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg, twice daily, added to contingency management